Celavie Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Celavie Biosciences's estimated annual revenue is currently $2M per year.
- Celavie Biosciences's estimated revenue per employee is $155,000
Employee Data
- Celavie Biosciences has 13 Employees.
- Celavie Biosciences grew their employee count by 18% last year.
Celavie Biosciences's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder/CEO | Reveal Email/Phone |
2 | Senior Researcher/Laboratory Manager | Reveal Email/Phone |
3 | CRO | Reveal Email/Phone |
4 | Sr Researcher | Reveal Email/Phone |
Celavie Biosciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Celavie Biosciences?
Celavie Biosciences is a privately-held company whose mission is to improve lives and restore hope by advancing regenerative stem cell therapies for the treatment of Parkinson’s disease and other disorders of the central nervous system (CNS). The company develops undifferentiated, unmodified allogeneic pluripotent stem cell-based therapies, holds a strong IP portfolio, including 18 issued patents, and has an experienced management team blending expertise in concept and cell technology, product scalability and entrepreneurship. Celavet, a subsidiary, applies the same proprietary technologies for the treatment and prevention of serious veterinary diseases.
keywords:N/AN/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.3M | 14 | 8% | N/A |
#2 | $3.5M | 15 | -12% | N/A |
#3 | $3.5M | 15 | 15% | N/A |
#4 | $1.5M | 18 | 6% | N/A |
#5 | $1.7M | 19 | 19% | N/A |